SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
GrowthFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

GHRP-2

Also known as pralmorelin, kp-102, ghrp-2 · Wikipedia

GHRP-2 (pralmorelin, KP-102) is a synthetic hexapeptide growth-hormone secretagogue and potent agonist at the ghrelin receptor (GHS-R1a). It elicits a rapid, dose-dependent pulse of pituitary growth hormone release and, to a smaller degree, stimulates appetite. The only regulatory approval is in Japan (as Ghrelyn) for single-dose diagnostic GH stimulation testing in suspected adult growth hormone deficiency at a 100-mcg intravenous dose (Chihara et al., Endocrine Journal 2007). Outside Japan it is sold as a research chemical. Synonyms include pralmorelin, KP-102, GPA-748, and GHRP-2. No approval exists in the US, EU, or other major markets.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs and the arcuate nucleus. Receptor activation signals through Gq/11 to phospholipase C, IP3, and intracellular calcium release, triggering vesicular GH exocytosis.

GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs and the arcuate nucleus. Receptor activation signals through Gq/11 to phospholipase C, IP3, and intracellular calcium release, triggering vesicular GH exocytosis. Centrally, GHRP-2 amplifies hypothalamic GHRH secretion and suppresses somatostatin tone, producing a synergistic GH pulse when co-administered with a GHRH analog (Bowers et al.). Compared with hexarelin, GHRP-2 causes less cortisol and prolactin elevation; compared with GHRP-6, it produces less appetite stimulation but more than ipamorelin. Pralmorelin has been validated as a diagnostic GH-stimulation test in adult GHD (Chihara et al., Endocrine Journal 2007).

Pharmacokinetic properties

Half-life

~15-60 minutes (estimates vary by route; ~15-20 min IV)

Routes

subcutaneous · intravenous · intranasal

Bioavailability

Short-acting; oral bioavailability poor. Diagnostic IV dose 100 mcg in Japan.

Amino-acid sequence

D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2

Use & research dosing

GH ReleaseAppetite StimulationAppetite Control

Diagnostic use in Japan (Ghrelyn): a single 100-mcg intravenous bolus after overnight fasting, with serial GH sampling over 120 minutes. A peak GH <15 mcg/L is the validated diagnostic threshold for adult GHD (Chihara et al., Endocrine Journal 2007). In research-chemical self-experimentation, protocols commonly report 100-300 mcg subcutaneously 1-3 times per day, often paired with a GHRH analog such as CJC-1295 or sermorelin. These chronic-dosing schedules are not derived from controlled human PK or safety data.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

GHRP-2 has the strongest acute GH-releasing potency among commonly used GHRPs aside from hexarelin, with a more tolerable cortisol/prolactin profile than hexarelin but less selectivity than ipamorelin. Its only regulatory niche is the Japanese diagnostic test for adult GHD, where a single 100-mcg IV dose has been validated against the insulin tolerance test. Chronic therapeutic dosing has never advanced to approval. All US sales are research-grade.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not FDA-approved (approved in Japan only, for single-dose diagnostic use)
  • Mild cortisol and prolactin elevation with each dose; cumulative effect with chronic dosing unclear
  • Appetite stimulation (less than GHRP-6, more than ipamorelin)
  • Avoid in active or suspected malignancy (GH/IGF-1 axis stimulation is a theoretical mitogenic signal)
  • Avoid in pregnancy and breastfeeding (no safety data)
  • May cause flushing, head rush, fluid retention, transient hyperglycaemia
  • Receptor desensitisation possible with chronic dosing; tachyphylaxis reported
  • Research-grade material purity is variable; injection-site reactions reported

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/17609397/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/15230633/

Facts verified

2026-05-25

Confidence

medium

What this means

  • approved only in Japan (Ghrelyn) for single-dose diagnostic use
  • no approval for chronic therapeutic dosing in any jurisdiction
  • chronic self-dosing protocols not supported by controlled human data

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.